Clinical trial
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial…
NCT00045682 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00045682 |
|---|---|
| Title | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation of CT-2103 in the Third-Line Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Cancer |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma |
| Intervention type | Drug |
| Interventions | Paclitaxel Poliglumex |
| Enrollment | 78 |
| Start date | Sep 1, 2002 |
| Primary completion | Jul 15, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: